Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA COX-2 Review Will Include Input From Furberg, Full Rx Safety Advisory Cmte.

This article was originally published in The Pink Sheet Daily

Executive Summary

After initially being asked not to appear at the meeting, Wake Forest's Furberg is formally re-invited to participate at the Feb 16-18 advisory committee meeting. FDA first invited only two members of the drug safety committee but has expanded its invitation to the full committee.
Advertisement

Related Content

COX-2 Use Should Be Limited, FDA Advisory Cmte. Member Furberg Says In NEJM
COX-2 Use Should Be Limited, FDA Advisory Cmte. Member Furberg Says In NEJM
FDA Drug Safety Advisory Cmte. Adds Harvard's Platt Ahead Of COX-2 Review
FDA Drug Safety Advisory Cmte. Adds Harvard's Platt Ahead Of COX-2 Review
COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk
COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk
FDA May Allow Furberg To Participate In COX-2 Advisory Committee
Bextra Meta-Analyses Could Be Taken Up At February COX-2 Advisory Cmte.

Topics

Advertisement
UsernamePublicRestriction

Register

PS061682

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel